Biological insights from clinical trials with anti-TNF therapy.
Feldmann
M
M
Kennedy Institute of Rheumatology, Hammersmith, London, GB.
Charles
P
P
Taylor
P
P
Maini
R N
RN
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D002634:Chemotaxis, Leukocyte; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D000069285:Infliximab; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D007958:Leukocyte Count; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D019087:Selectins / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007074:Immunoglobulin G; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D019087:Selectins; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; C099374:Ro 45-2081; D000069285:Infliximab; D000068800:Etanercept